Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 91 to 105 of 185 results for advanced breast cancer

  1. Neoadjuvant endocrine therapy in postmenopausal women:- Is there a benefit for neoadjuvant endocrine therapy in postmenopausal women with early breast cancer?

    for neoadjuvant endocrine therapy in postmenopausal women with early breast cancer? Any explanatory notes(if applicable) To...

    Research recommendation
    Published
    11 December 2018

  2. Microwave ablation for primary or metastatic cancer in the lung (IPG716)

    Evidence-based recommendations on microwave ablation for primary or metastatic cancer in the lung in adults. This involves inserting a probe into the lung, through the skin of the chest, to send microwaves into the cancer cells. This produces heat, aiming to destroy the cancer (ablation).

    Interventional procedures guidance
    Published
    2 February 2022
    View recommendations

    Sections for IPG716

  3. Neoadjuvant treatment:- What are the indications for postmastectomy radiotherapy after neoadjuvant chemotherapy?

    guidance details Comes from guidance Early and locally advanced breast cancer: diagnosis and management Number NG101 Date issued

    Research recommendation
    Published
    11 December 2018

  4. Interim process and methods guide for the clinical guideline updates using standing committees pilot programme 2013 (PMG17)

    Interim process and methods guide for the clinical guideline updates using standing committees pilot programme 2013

  5. NICE responds to failure of talks to reach price agreement on Enhertu

    Talks with the makers of Enhertu have ended without agreement, meaning guidance that does not recommend Enhertu for advanced breast cancer will remain unchanged.

    News
    Last updated
    19 November 2024

  6. Caris Molecular Intelligence for guiding cancer treatment (MIB120)

    NICE has developed a medtech innovation briefing (MIB) on Caris Molecular Intelligence for guiding cancer treatment .

    Medtech innovation briefing
    Published
    20 September 2017

  7. Spinal metastases and metastatic spinal cord compression (NG234)

    This guideline covers recognition, referral, investigation and management of spinal metastases and metastatic spinal cord compression (MSCC). It is also relevant for direct malignant infiltration of the spine and associated cord compression. It aims to improve early diagnosis and treatment to prevent neurological injury and improve prognosis.

    NICE guideline
    Published
    6 September 2023
    View recommendations

    Sections for NG234

  8. Sunitinib in combination with capecitabine for the treatment of advanced and/or metastatic breast cancer [ID319]

    Discontinued [GID-TAG410]

    Technology appraisal guidance
    Discontinued

  9. What is the role of arm and shoulder specific exercises compared with and/or used as an adjunct to established lymphoedema treatments (such as compression garments and complex decongestive therapy)?

    measures. Source guidance details Comes from guidance Advanced breast cancer: diagnosis and treatment Number CG81 Date issued

    Research recommendation
    Published
    6 July 2015

  10. Irreversible electroporation for treating primary lung cancer and metastases in the lung (IPG441)

    Evidence-based recommendations on irreversible electroporation for treating primary lung cancer and metastases in the lung. This involves using electrical pulses to kill cancer cells.

    Interventional procedures guidance
    Published
    23 February 2013
    View recommendations

    Sections for IPG441

  11. Sunitinib in combination with a taxane for the first line treatment of advanced and/or metastatic breast cancer [ID58]

    Discontinued [GID-TAG391]

    Technology appraisal guidance
    Discontinued

  12. Inavolisib with palbociclib and fulvestrant for treating HR+/HER2-, PIK3CA mutated locally advanced or metastatic breast cancer TS ID 11990

    Awaiting development [GID-TA11519] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [ID6165]

    In development [GID-TA11318] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. OSNA for colon cancer staging (MIB77)

    NICE has developed a medtech innovation briefing (MIB) on OSNA for colon cancer staging

    Medtech innovation briefing
    Published
    24 August 2016

  15. NICE ready to work with company to address uncertainty in evidence for elacestrant for advanced breast cancer

    Today (1 October 2024) NICE is consulting on draft guidance that does not recommend elacestrant for treating a type of advanced breast cancer.

    News
    Last updated
    1 October 2024